Gene therapy for neovascular age-related macular degeneration: rationale, clinical trials and future directions
Open accessThe DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Abstract
Age-related macular degeneration (AMD) is one of the leading causes of irreversible blindness in the developed world. Antivascular endothelial growth factor therapy has transformed the management and outcome of neovascular AMD (nAMD), although the need for repeated intravitreal injections—even lifelong—and the related complications, high drug costs, frequent clinic visits and repeated imaging have resulted in an enormous burden both to healthcare systems and patients. The application of gene therapy approaches for sustained delivery of a range of antiangiogenic proteins has the promise of helping to address these aforementioned challenges. A number of early phase clinical trials of gene therapy in nAMD have provided encouraging results, with many more ongoing or anticipated. There remain significant areas of controversy, including regarding the optimal treatment targets, routes of administration and potential safety concerns. In this review we aim to provide an update of the current status of gene therapy for nAMD and briefly discuss future prospects.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
VEGF in signaling and disease: beyond discovery and development
Apte, R. S., Chen, D. S., & Ferrara, N. (2019) · Cell · doi:10.1016/j.cell.2019.01.021 · Cited by 2,721 · cited 1×
“17 Although several factors are involved in this physiological process, including placental growth factor (PIGF), platelet-derived growth factor (PDGF-β ), angiopoietin-1 (Ang1) and angiopoietin-2 (Ang2), VEGF plays the major role, primarily regulating vascular permeability and neovascularisation.”
BackgroundMacLaren, R. E., Groppe, M., Barnard, A. R., Cottriall, C. L., Tolmachova, T., Seymour, L., Clark, K. R., During, M. J., Cremers, F. P. M., Black, G. C. M., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(13)62117-0 · Cited by 796
Long-Term Effect of Gene Therapy on Leber’s Congenital Amaurosis
Bainbridge, J. W. B., Mehat, M. S., Sundaram, V., Robbie, S. J., Barker, S. E., Ripamonti, C., Georgiadis, A., Mowat, F. M., Beattie, S. G., Gardner, P. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1414221 · Cited by 743 · cited 1×
“13–15 Gene therapy for nAMD is on the verge of transforming management and outcomes, as intravitreal anti-VEGF agents did a decade ago.”
BackgroundSelf-citationDalkara, D., Byrne, L. C., Klimczak, R. R., Visel, M., Yin, L., Merigan, W. H., Flannery, J. G., & Schaffer, D. V. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3005708 · Cited by 734
Maguire, M. G., Martin, D. F., Ying, G.-S., Jaffe, G. J., Daniel, E., Grunwald, J. E., Toth, C. A., Ferris, F. L., & Fine, S. L. (2016) · Ophthalmology · doi:10.1016/j.ophtha.2016.03.045 · Cited by 708
Quantitative analysis of the packaging capacity of recombinant adeno-associated virus
Dong, J.-Y., Fan, P.-D., & Frizzell, R. A. (1996) · Human Gene Therapy · doi:10.1089/hum.1996.7.17-2101 · Cited by 583 · cited 1×
“34 35 Several strategies have been investigated to bypass this cargo capacity, including directed evolution and the generation of dual AAV vectors.”
BackgroundInner limiting membrane barriers to aav-mediated retinal transduction from the vitreous
Dalkara, D., Kolstad, K. D., Caporale, N., Visel, M., Klimczak, R. R., Schaffer, D. V., & Flannery, J. G. (2009) · Molecular Therapy · doi:10.1038/mt.2009.181 · Cited by 357
Singer, M. A., Awh, C. C., Sadda, S., Freeman, W. R., Antoszyk, A. N., Wong, P., & Tuomi, L. (2012) · Ophthalmology · doi:10.1016/j.ophtha.2011.12.016 · Cited by 356 · cited 1×
“9–11 Moreover, a recent meta-analysis suggested that treatment intensity correlated directly with final visual outcomes (with real-world experience often being of ‘under-treatment’ and thereby inferior outcomes compared with those achieved in pivotal clinical trials), further highlighting the need…”
ResultImmune Responses to AAV in Clinical Trials
Mingozzi, F., & A. High, K. (2011) · Current Gene Therapy · doi:10.2174/156652311796150354 · Cited by 324
Effective delivery of large genes to the retina by dual AAV vectors
Trapani, I., Colella, P., Sommella, A., Iodice, C., Cesi, G., de Simone, S., Marrocco, E., Rossi, S., Giunti, M., Palfi, A., et al. (2014) · EMBO Molecular Medicine · doi:10.1002/emmm.201302948 · Cited by 269
Research works printed but not linked: 57
- 10.1136/bjophthalmol-2017-310368 · DOI
- Keel, 2017, Prevalence of age-related macular degeneration in Australia: the Australian National eye health survey, JAMA Ophthalmol, 135, 1242, 10.1001/jamaophthalmol.2017.4182 · DOI
- Wilde, 2017, Prevalence of age-related macular degeneration in an elderly UK Caucasian population-The Bridlington eye assessment project: a cross-sectional study, Eye, 31, 1042, 10.1038/eye.2017.30 · DOI
- Wong, 2014, Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis, Lancet Glob Health, 2, e106, 10.1016/S2214-109X(13)70145-1 · DOI · Paper page
- 10.1136/bjophthalmol-2019-314422 · DOI · Paper page
- 10.1016/j.ophtha.2012.10.036 · DOI · Paper page
- Lai, 2015, Current choice of treatments for neovascular AMD, Expert Rev Clin Pharmacol, 8, 135, 10.1586/17512433.2015.990379 · DOI
- 10.1016/j.ophtha.2013.01.057 · DOI
- 10.1016/j.ajo.2012.06.031 · DOI
- Hussain, 2017, Treatment Burden in Neovascular AMD:Visual Acuity Outcomes are Associated With Anti-VEGF Injection Frequency, Ophthalmic Surg Lasers Imaging Retina, 48, 780, 10.3928/23258160-20170928-01 · DOI
- 10.1016/j.ophtha.2012.11.048 · DOI · Paper page
- 10.1016/j.ophtha.2016.03.003 · DOI · Paper page
- Rosen, 2002, Clinical experience with angiogenesis signaling inhibitors: focus on vascular endothelial growth factor (VEGF) blockers, Cancer Control, 9, 36, 10.1177/107327480200902S05 · DOI · Paper page
- 10.1167/iovs.02-1092 · DOI · Paper page
- 10.1097/BCR.0b013e3181c7ed82 · DOI · Paper page
- 10.1042/CS20040370 · DOI · Paper page
- 10.1210/er.2003-0027 · DOI · Paper page
- 10.1016/S0002-9440(10)64525-7 · DOI · Paper page
- 10.1038/nrc2505 · DOI · Paper page
- Dehghanian, 2014, New insights into VEGF-A alternative splicing: key regulatory switching in the pathological process, Avicenna J Med Biotechnol, 6, 192
- 10.1093/nar/gkt539 · DOI · Paper page
- 10.1016/j.it.2004.05.003 · DOI · Paper page
- 10.1016/0006-291X(92)90483-2 · DOI · Paper page
- 10.1073/pnas.88.20.9267 · DOI · Paper page
- 10.1126/science.1312256 · DOI · Paper page
- 10.1093/bmb/ldy005 · DOI · Paper page
- 10.1128/JVI.76.2.791-801.2002 · DOI · Paper page
- 10.1007/978-1-4614-3209-8_86 · DOI
- 10.1089/hum.2017.172 · DOI
- 10.2174/1566523054065039 · DOI · Paper page
- Li, 2008, Intraocular route of AAV2 vector administration defines humoral immune response and therapeutic potential, Mol Vis, 14, 1760
- Bruewer, 2013, Evaluation of lateral spread of transgene expression following subretinal AAV-mediated gene delivery in dogs, PLoS One, 8, 10.1371/journal.pone.0060218 · DOI · Paper page
- 10.1038/mt.2008.41 · DOI · Paper page
- Reid, 2017, Improvement of photoreceptor targeting via intravitreal delivery in mouse and human retina using combinatory rAAV2 capsid mutant vectors, Invest Ophthalmol Vis Sci, 58, 6429, 10.1167/iovs.17-22281 · DOI
- Jüttner, 2019, Targeting neuronal and glial cell types with synthetic promoter AAVs in mice, non-human primates and humans, Nat Neurosci, 22, 1345, 10.1038/s41593-019-0431-2 · DOI · Paper page
- Ali, 1998, Adeno-Associated virus gene transfer to mouse retina, Hum Gene Ther, 9, 81, 10.1089/hum.1998.9.1-81 · DOI
- Habot-Wilner, 2019, Suprachoroidally injected pharmacological agents for the treatment of chorio-retinal diseases: a targeted approach, Acta Ophthalmol, 97, 460, 10.1111/aos.14042 · DOI · Paper page
- 10.1016/j.jcrs.2007.03.051 · DOI · Paper page
- Jung, 2019, Targeting drug delivery within the suprachoroidal space, Drug Discov Today, 24, 1654, 10.1016/j.drudis.2019.03.027 · DOI
- 10.1159/000336045 · DOI
- Yeh, 2019, Suprachoroidal injection of triamcinolone acetonide, CLS-TA, for macular edema due to noninfectious uveitis: a randomized, phase 2 study (DOGWOOD), Retina, 39, 1880, 10.1097/IAE.0000000000002279 · DOI
- Rasmussen, 2001, Clinical protocol. An open-label, phase I, single administration, dose-escalation study of ADGVPEDF.11D (ADPEDF) in neovascular age-related macular degeneration (AMD), Hum Gene Ther, 12, 2029
- 10.1089/hum.2006.17.167 · DOI · Paper page
- 10.1073/pnas.90.22.10705 · DOI · Paper page
- 10.1089/hum.2012.008 · DOI · Paper page
- Campochiaro, 2017, Lentiviral vector gene transfer of Endostatin/Angiostatin for macular degeneration (GEM) study, Hum Gene Ther, 28, 99, 10.1089/hum.2016.117 · DOI · Paper page
- Kumar-Singh, 2019, The role of complement membrane attack complex in dry and wet AMD - From hypothesis to clinical trials, Exp Eye Res, 184, 266, 10.1016/j.exer.2019.05.006 · DOI
- 10.1101/gad.1653708 · DOI · Paper page
- Hussain, 2017, Emerging vascular endothelial growth factor antagonists to treat neovascular age-related macular degeneration, Expert Opin Emerg Drugs, 22, 235, 10.1080/14728214.2017.1362390 · DOI
- 10.1038/nrm2639 · DOI · Paper page
- 10.1167/iovs.14-13897 · DOI
- 10.1126/sciadv.aau6732 · DOI
- Xia, 2008, Inhibition of retinal neovascularization by siRNA targeting VEGF(165), Mol Vis, 14, 1965
- Garba, 2010, Bevasiranib for the treatment of wet, age-related macular degeneration, Ophthalmol Eye Dis, 2, OED.S4878, 10.4137/OED.S4878 · DOI · Paper page
- 10.1016/j.ajo.2010.02.006 · DOI · Paper page
- 10.1002/jgm.2678 · DOI · Paper page
- 10.1002/jgm.2623 · DOI
Cited by
Lee, K. S., Lin, S., Copland, D. A., Dick, A. D., & Liu, J. (2021) · Journal of Neuroinflammation · doi:10.1186/s12974-021-02088-0 · Cited by 150
Ocular Gene Therapy: A Literature Review with Special Focus on Immune and Inflammatory Responses
Ghoraba, H. H., Akhavanrezayat, A., Karaca, I., Yavari, N., Lajevardi, S., Hwang, J., Regenold, J., Matsumiya, W., Pham, B., Zaidi, M., et al. (2022) · Clinical Ophthalmology · doi:10.2147/opth.s364200 · Cited by 76
“cells can produce the desired drugs in vivo.(2) This concept has considerable potential; patients can be treated once, and their tissues are transformed into bio-factories that produce the medications indefinitely.”
BackgroundMICHAELIDES, M., BESIRLI, C. G., YANG, Y., DE GUIMARAES, T. A. C., WONG, S. C., HUCKFELDT, R. M., COMANDER, J. I., SAHEL, J.-A., SHAH, S. M., TEE, J. J. L., et al. (2024) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2024.05.034 · Cited by 55
Self-citationRNA-targeting strategies as a platform for ocular gene therapy
Kumar, S., Fry, L. E., Wang, J.-H., Martin, K. R., Hewitt, A. W., Chen, F. K., & Liu, G.-S. (2023) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2022.101110 · Cited by 51
Fan, X., Jiang, K., Geng, F., Lu, W., & Wei, G. (2023) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2023.114864 · Cited by 33
Metadata
- Authors
- Guimaraes, T. A. C. D., Georgiou, M., Bainbridge, J. W. B., & Michaelides, M.
- Venue
- British Journal of Ophthalmology
- Publisher
- BMJ
- Published
- 2020-04-08
- Volume
- 105
- Issue
- 2
- Pages
- 151-157
- ISSN
- 0007-1161 (ISSN-L)
- 1468-2079
- OpenAlex
- W3015569704
- Cited by
- 91
- References
- 25
- FWCI
- 9.58
- Type
- journal article
- Language
- en
- Open access
- hybrid
- Funders
- National Institute for Health Research Biomedical Research Centre at Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of Ophthalmology (NA)
- Foundation Fighting Blindness (NA)
- Retina UK (NA)
- Wellcome Trust (099173/Z/12/Z)
- Fight for Sight (NA)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Gene therapy for neovascular age-related macular degeneration: rationale, clinical trials and future directions. https://app.cochat.ai/papers/10.1136/bjophthalmol-2020-316195
- The paper
- Guimaraes, T. A. C. D., Georgiou, M., Bainbridge, J. W. B., & Michaelides, M. (2021). Gene therapy for neovascular age-related macular degeneration: rationale, clinical trials and future directions. British Journal of Ophthalmology. https://doi.org/10.1136/bjophthalmol-2020-316195
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.